Protein Malabsorption
Conditions
Brief summary
The purpose of this study is to examine the pattern of plasma amino acid appearance after a two-week daily regimen of milk protein concentrate supplementation with and without the addition of Bacillus coagulans GBI-30, 6086 among older women.
Detailed description
Once determined eligible and providing consent, participants will be assigned in a randomized, double-blind, crossover fashion to ingest a single daily 25-gram dose of a milk protein concentrate or a similar dose of milk protein concentrate plus bacillus coagulans GBI-30, 6086. Upon arrival for each study visit, participants will have their resting heart rate, blood pressure, body mass, height, and body composition measured. Upon ingestion of their final assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect approximately 10mL of venous blood from a forearm vein at specific time intervals up to four hours after ingestion of their final assigned supplementation dose for that period in the study protocol.
Interventions
DIETARY_SUPPLEMENTBacillus Coagulans GBI-30, 6086
In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
Sponsors
Increnovo, LLC
Lindenwood University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
Supplements blinded to participant and investigator by third party
Intervention model description
Randomized, double-blind, crossover study design
Eligibility
Sex/Gender
FEMALE
Age
50 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* All participants will be between the ages of 50-70 years * Completing at least 30 minutes of physical activity at minimum three days per week
Exclusion criteria
* As indicated on a medical history form they complete, any individual who is currently being treated for or diagnosed with a cardiac, respiratory, circulatory, musculoskeletal, metabolic, obesity (defined as body mass index \> 30 kg/m2), immune, autoimmune, psychiatric, hematological, neurological or endocrinological disorder or disease * Any woman who is taking a medication known to impact digestive function or hormonal functions that may impact how our body digests, absorbs, or metabolizes nutrients * Any woman currently taking a probiotic or a dietary supplement that may impact digestive function or hormonal functions that may impact how our body digests, absorbs, or metabolizes nutrients * Participants who are determined to not be weight stable defined as measured body mass deviating by 2% or more. * Participants who do not or are not willing to abstain from alcohol, nicotine, and caffeine for overnight (8-10 hours) * Participants who do not or are not willing to abstain from exercise for 24 hours prior to each visit * Women who are pregnant * Women who are lactose intolerant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentrations of Amino Acids in Blood | 4 hours | Plasma Concentrations of Amino Acids in Blood |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 4 hours | Incidence and associations of reported adverse events |
Countries
United States
Outcome results
None listed